PL422220A1 - Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania - Google Patents

Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Info

Publication number
PL422220A1
PL422220A1 PL422220A PL42222017A PL422220A1 PL 422220 A1 PL422220 A1 PL 422220A1 PL 422220 A PL422220 A PL 422220A PL 42222017 A PL42222017 A PL 42222017A PL 422220 A1 PL422220 A1 PL 422220A1
Authority
PL
Poland
Prior art keywords
syrup
obtaining
pharmaceutical composition
zinc gluconate
favourably
Prior art date
Application number
PL422220A
Other languages
English (en)
Other versions
PL239019B1 (pl
Inventor
Hanna WAHL
Marek DĄBROWA
Anna OSTROWSKA
Małgorzata Kowalska-Parteka
Jarosław PASIŃSKI
Arkadiusz MADEJCZYK
Original Assignee
Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority to PL422220A priority Critical patent/PL239019B1/pl
Priority to RU2020106791A priority patent/RU2778647C2/ru
Priority to AU2018301189A priority patent/AU2018301189A1/en
Priority to PCT/PL2018/050029 priority patent/WO2019013658A1/en
Priority to EP18831595.6A priority patent/EP3651803A4/en
Priority to UAA202000918A priority patent/UA127658C2/uk
Priority to US16/631,026 priority patent/US11135162B2/en
Publication of PL422220A1 publication Critical patent/PL422220A1/pl
Publication of PL239019B1 publication Critical patent/PL239019B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonian cynku, charakteryzująca się tym, że zawiera substancję słodzącą wybraną z grupy disacharydów, korzystnie sacharozę lub/i z grupy polioli, korzystnie maltitol, substancję ułatwiającą rozpuszczanie z grupy alkoholi wodorotlenowych lub ich mieszanin, korzystnie glikol propylenowy, glicerol, substancje konserwujące wybrane z grupy estrów kwasu parahydroksybenzoesowego i ich mieszanin, korzystnie metyluparahydroksybenzoesan, propylu parahydroksybenzoesanu, słodzik, korzystnie sacharynę sodową lub sukralozę oraz substancje ustalające pH roztworu w zakresie od 5,7 do 12,0 korzystnie aromat oraz jej sposób otrzymywania. Zgłoszenie, ponadto, dotyczy sposobu otrzymywania przedmiotowej kompozycji.
PL422220A 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania PL239019B1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
RU2020106791A RU2778647C2 (ru) 2017-07-14 2018-06-21 Фармацевтическая композиция в виде водного раствора, предпочтительно сиропа, содержащая инозина пранобекс и глюконат цинка, и способ ее получения
AU2018301189A AU2018301189A1 (en) 2017-07-14 2018-06-21 A pharmaceutical composition in the form of an aqueous solution, preferably a syrup, containing inosine pranobex and zinc gluconate and a method of preparation thereof
PCT/PL2018/050029 WO2019013658A1 (en) 2017-07-14 2018-06-21 PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS SOLUTION, PREFERABLY SYRUP, CONTAINING PRANOBEX INOSINE AND ZINC GLUCONATE AND PREPARATION METHOD THEREOF
EP18831595.6A EP3651803A4 (en) 2017-07-14 2018-06-21 PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS SOLUTION, PREFERABLY A SYRUP, CONTAINING INOSINE PRANOBEX AND ZINC GLUCONATE AND PROCESS FOR PREPARATION
UAA202000918A UA127658C2 (uk) 2017-07-14 2018-06-21 Фармацевтична композиція у вигляді водного розчину, переважно сиропу, що містить інозин пранобекс і глюконат цинку, і спосіб її отримання
US16/631,026 US11135162B2 (en) 2017-07-14 2018-06-21 Pharmaceutical composition in the form of an aqueous solution, 1A syrup, containing inosine pranobex and zinc gluconate and a method of preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Publications (2)

Publication Number Publication Date
PL422220A1 true PL422220A1 (pl) 2019-01-28
PL239019B1 PL239019B1 (pl) 2021-10-25

Family

ID=65002643

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Country Status (6)

Country Link
US (1) US11135162B2 (pl)
EP (1) EP3651803A4 (pl)
AU (1) AU2018301189A1 (pl)
PL (1) PL239019B1 (pl)
UA (1) UA127658C2 (pl)
WO (1) WO2019013658A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL239019B1 (pl) * 2017-07-14 2021-10-25 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
PL238168B1 (pl) * 2019-02-04 2021-07-12 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie
EP4259151A4 (en) * 2020-12-10 2025-01-29 Reena Patel Methisoprinol compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131618A (ja) * 2004-10-04 2006-05-25 Taisho Pharmaceut Co Ltd 亜鉛化合物配合組成物
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
UA32464U (uk) * 2008-02-20 2008-05-12 Univ Oo Bohomolets Nat Medical Спосіб комплексного лікування дітей, хворих на хронічну форму епштейна-барр вірусної інфекції
WO2012096655A1 (en) * 2011-01-11 2012-07-19 Sam Poon Ang Compositions for treating chronic viral infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121093A1 (en) * 1999-04-06 2006-06-08 Ream Ronald L Tableted products including active agent
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US7026298B2 (en) * 2001-06-04 2006-04-11 Abbott Laboratories Oral rehydration compositions
WO2006061351A1 (en) * 2004-12-06 2006-06-15 Janssen Pharmaceutica N.V. Oral suspension comprising meloxicam
US20090016990A1 (en) * 2007-01-24 2009-01-15 Alberte Randall S Antimicrobial Compositions
US8362083B2 (en) * 2008-01-15 2013-01-29 C.B. Fleet Company Inc. Taste-masked docusate compositions
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
KR20140012651A (ko) * 2011-01-24 2014-02-03 안테리오스, 인코퍼레이티드 파라벤 조성물
CA2858372A1 (en) * 2011-11-10 2013-05-16 Lankenau Institute For Medical Research Compositions and methods for the prevention of microbial infections
RU2557962C1 (ru) * 2014-07-03 2015-07-27 Искандар Халиуллович Исмагилов Фармацевтическая композиция на основе метизопринола для перорального введения
ES2732729T3 (es) * 2014-12-25 2019-11-25 Sanovel Ilac Sanayi Ve Ticaret As Composiciones farmacéuticas acuosas tópicas orales de flurbiprofeno y dexpantenol
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
UA124498C2 (uk) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти)
PL239019B1 (pl) * 2017-07-14 2021-10-25 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131618A (ja) * 2004-10-04 2006-05-25 Taisho Pharmaceut Co Ltd 亜鉛化合物配合組成物
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
UA32464U (uk) * 2008-02-20 2008-05-12 Univ Oo Bohomolets Nat Medical Спосіб комплексного лікування дітей, хворих на хронічну форму епштейна-барр вірусної інфекції
WO2012096655A1 (en) * 2011-01-11 2012-07-19 Sam Poon Ang Compositions for treating chronic viral infections

Also Published As

Publication number Publication date
UA127658C2 (uk) 2023-11-22
AU2018301189A1 (en) 2020-02-13
WO2019013658A1 (en) 2019-01-17
EP3651803A4 (en) 2021-03-24
RU2020106791A3 (pl) 2021-09-29
EP3651803A1 (en) 2020-05-20
PL239019B1 (pl) 2021-10-25
US11135162B2 (en) 2021-10-05
RU2020106791A (ru) 2021-08-16
US20200138709A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
PL422220A1 (pl) Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
ATE545341T1 (de) Gelierungszusammensetzungen und -verfahren
HRP20171270T1 (hr) Liofilizirani spoj
BR112015017912A2 (pt) composto, composições ingeríveis e de acentuação da doçura, formulação de concentrado aromatizante e método para aumentar o sabor doce de composição
HRP20241282T1 (hr) Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid
HRP20191011T1 (hr) Pripravak za liječenje akni
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
EP4011353A1 (en) New cosmetics solvents comprising ascorbic acid
ITTO20110488A1 (it) Bevanda per migliorare la condizione della pelle
MX387286B (es) Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
KR101837446B1 (ko) 알파-망고스틴, 베타-망고스틴, 감마-망고스틴 또는 가르탄닌 화합물을 유효성분으로 함유하는 피부 주름 개선 또는 피부 보습용 조성물
MX2014000195A (es) Enmascaramiento del amargor.
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador
ITTO20120714A1 (it) Integratore alimentare per migliorare la salute del tessuto connettivo
KR20170097013A (ko) 어드히런스 정션 기능 강화제
EA201791071A1 (ru) Производство замороженных кондитерских изделий
JP7333751B2 (ja) ヒト抗菌ペプチド産生促進剤
UA112541C2 (uk) Застосування гідрохлориду амброксолу для лікування гострого фарингіту
HRP20210717T1 (hr) Spoj koji stimulira kolagen i elastin i topikalni sastavi koji sadrže takav spoj
WO2024065763A1 (en) Composition for caring for keratin materials
KR102309956B1 (ko) 카모마일 꽃 분말을 포함하는 피부 혈행 개선용 조성물
ES2749645T3 (es) Loción contra la caída del cabello
JP5996706B1 (ja) ツルムラサキエキス及びその美白、日焼け防止の用途への使用